You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 19, May 21, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (22)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Statistics and Research Methods
 •Randomized Controlled Trial
 •Alert me on articles by topic

Clinical Trials—Multiple Treatments, Multiple End Points, and Multiple Lessons

Michael S. Lauer, MD; Eric J. Topol, MD

JAMA. 2003;289:2575-2577.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 1986, the GISSI group1 published a report of a large randomized clinical trial demonstrating that intravenous streptokinase reduces the risk of death among patients with acute myocardial infarction. The design of the trial was simple, as was the published report. There was one treatment, intravenous streptokinase, whereas the control group received no streptokinase. There was no blinding and no placebo. The end point of interest was death from any cause during hospitalization.

Since the publication of the landmark GISSI-1 trial, many more randomized trials have been performed and their results published. However, as noted in 2 articles published in this issue of THE JOURNAL, the nature of clinical trials and their reporting has become more complex. Freemantle and colleagues2 address the issue of trials that focus on composite end points that consist of multiple outcomes, rather than on a single end . . . [Full Text of this Article]

Author Affiliations: Department of Cardiovascular Medicine (Drs Lauer and Topol), Cleveland Clinic Foundation, Cleveland, Ohio; and JAMA (Dr Lauer).


RELATED ARTICLES

Analysis and Reporting of Factorial Trials: A Systematic Review
Finlay A. McAlister, Sharon E. Straus, David L. Sackett, and Douglas G. Altman
JAMA. 2003;289(19):2545-2553.
ABSTRACT | FULL TEXT  

Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Nick Freemantle, Melanie Calvert, John Wood, Joanne Eastaugh, and Carl Griffin
JAMA. 2003;289(19):2554-2559.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death: A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention
Goldberger et al.
J Am Coll Cardiol 2008;0:j.jacc.2008.05.003v1-13938.
FULL TEXT  

Randomized Clinical Trials and Observational Studies: Guidelines for Assessing Respective Strengths and Limitations
Hannan
J Am Coll Cardiol Intv 2008;1:211-217.
ABSTRACT | FULL TEXT  

The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design
Knoll et al.
Nephrol Dial Transplant 2008;23:354-358.
ABSTRACT | FULL TEXT  

An Externally Validated Model for Predicting Long-Term Survival after Exercise Treadmill Testing in Patients with Suspected Coronary Artery Disease and a Normal Electrocardiogram
Lauer et al.
ANN INTERN MED 2007;147:821-828.
ABSTRACT | FULL TEXT  

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)
Sinclair et al.
Lupus 2007;16:972-980.
ABSTRACT  

Quantitative Measures of Electrocardiographic Left Ventricular Mass, Conduction, and Repolarization, and Long-Term Survival After Coronary Artery Bypass Grafting
Lauer et al.
Circulation 2007;116:888-893.
ABSTRACT | FULL TEXT  

Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease
Chan et al.
Circulation 2007;115:2398-2409.
ABSTRACT | FULL TEXT  

ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain: A Report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) Developed in Collaboration With the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography
Greenland et al.
J Am Coll Cardiol 2007;49:378-402.
FULL TEXT  

Keeping Apples and Oranges Separate: Reassessing Clinical Trials That Use Composite End Points as Their Primary Outcome
Chan et al.
J Am Coll Cardiol 2006;48:850-850.
FULL TEXT  

High-dose statins and the IDEAL study.
Chan et al.
JAMA 2006;295:2477-2477.
FULL TEXT  

Impact of Completeness of Percutaneous Coronary Intervention Revascularization on Long-Term Outcomes in the Stent Era
Hannan et al.
Circulation 2006;113:2406-2412.
ABSTRACT | FULL TEXT  

Long-Term Outcomes of Coronary-Artery Bypass Grafting versus Stent Implantation
Hannan et al.
NEJM 2005;352:2174-2183.
ABSTRACT | FULL TEXT  

Comparison of Self-Report, Hospital Discharge Codes, and Adjudication of Cardiovascular Events in the Women's Health Initiative
Heckbert et al.
Am J Epidemiol 2004;160:1152-1158.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.